(Bloomberg) — Moderna Inc. shares slid 3.5% on Friday as unease mounted about the biotech’s Covid-19 vaccine trial fueled by ongoing insider shares sales and an enrollment slowdown.With late-stage trial results weeks away, the stock has shed more than a third of its value from record highs in mid-July. Still, shares have more than tripled since the beginning of the year, prompting several insiders to cash out.Chief Executive Officer Stephane Bancel, who found himself a newly minted billionaire as a result of the pandemic, disposed of an additional 18,000 shares this week, including some tied to entities controlled by him.The …read more
Source:: Yahoo Finance
